CMND gets Yale IRB approval for CMND-100 Phase I/II Parts B and C recruitment
Clearmind Medicine received Yale IRB approval, enabling patient recruitment for Parts B and C of its CMND-100 Phase I/II trial following positive safety results.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.